Stay informed with the latest company announcements, scientific publications, clinical milestones, media coverage, conferences, partnerships, and events from Helio Genomics.
Our landmark CLiMB trial — the largest prospective, multicenter U.S. study of its kind — is now peer-reviewed and published, demonstrating HelioLiver's superior sensitivity for early-stage HCC versus ultrasound.
Read Full StoryHow rural healthcare is adopting collaborative, technology-enabled models for earlier detection and better outcomes.
Read moreHelio Genomics partnered with Syneos Health to drive adoption of its HelioLiver test for early HCC detection.
Read moreA strategic commercial partnership with Syneos Health to accelerate nationwide adoption of HelioLiver™.
Read moreHelio broadens access to HelioLiver through Quest Diagnostics’ nationwide network of patient service centers.
Read moreHelio joins the Rural Health Transformation Collaborative, co-chaired by Microsoft, to expand rural early detection.
Read moreHelio’s CEO reflects on the landmark CLiMB study and what earlier liver cancer detection means for patients.
Read moreA new partnership with Syneos Health to expand access to the HelioLiver blood test and speed up adoption.
Read moreA new partnership to expand commercialization of the blood-based HelioLiver test for early HCC detection.
Read moreA strategic collaboration to boost adoption of HelioLiver, the AI blood test for early liver cancer detection.
Read moreNo articles match your search.
Join the Helio Genomics team at conferences, symposiums, and webinars across the field — or revisit where we've recently been.
We're finalising our next conferences, symposiums, and webinars. Check back shortly for where to find the Helio Genomics team next.
Helio showcased results from three cancer detection studies at the 2025 Digestive Disease Week Conference.
More InfoThe presentation will dive into promising findings and their significant impact on the liver cancer landscape.
More Info